EP1320621A4 - Vaccins adenoviraux de premiere generation evolues, exprimant les proteines gag, pol et nef du vih-1 a optimisation des codons et leurs modifications - Google Patents

Vaccins adenoviraux de premiere generation evolues, exprimant les proteines gag, pol et nef du vih-1 a optimisation des codons et leurs modifications

Info

Publication number: EP1320621A4
Authority: EP; European Patent Office
Prior art keywords: hiv1; nef; pol; gag; enhanced
Prior art date: 2000-09-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP01975214A

Other languages

German (de)

English (en)

Other versions

EP1320621A2 (fr

Inventor

Emilio A Emini

Rima Youil

Andrew J Bett

Ling Chen

David C Kaslow

John W Shiver

Timothy J Toner

Danilo R Casimiro

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck and Co Inc

Original Assignee

Merck and Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-15

Filing date

2001-09-14

Publication date

2005-11-23

2001-09-14 Application filed by Merck and Co Inc filed Critical Merck and Co Inc

2003-06-25 Publication of EP1320621A2 publication Critical patent/EP1320621A2/fr

2005-11-23 Publication of EP1320621A4 publication Critical patent/EP1320621A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Animal Behavior & Ethology (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Communicable Diseases (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

EP01975214A 2000-09-15 2001-09-14 Vaccins adenoviraux de premiere generation evolues, exprimant les proteines gag, pol et nef du vih-1 a optimisation des codons et leurs modifications Withdrawn EP1320621A4 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US23318000P	2000-09-15	2000-09-15
US233180P		2000-09-15
PCT/US2001/028861 WO2002022080A2 (fr)	2000-09-15	2001-09-14	Vaccins adenoviraux de premiere generation evolues, exprimant les proteines gag, pol et nef du vih-1 a optimisation des codons et leurs modifications

Publications (2)

Publication Number	Publication Date
EP1320621A2 EP1320621A2 (fr)	2003-06-25
EP1320621A4 true EP1320621A4 (fr)	2005-11-23

Family

ID=22876220

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP01975214A Withdrawn EP1320621A4 (fr)	2000-09-15	2001-09-14	Vaccins adenoviraux de premiere generation evolues, exprimant les proteines gag, pol et nef du vih-1 a optimisation des codons et leurs modifications

Country Status (5)

Country	Link
EP (1)	EP1320621A4 (fr)
JP (1)	JP2004508064A (fr)
AU (2)	AU2001294562B2 (fr)
CA (1)	CA2422882A1 (fr)
WO (1)	WO2002022080A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU782193B2 (en) *	1999-12-17	2005-07-07	Merck & Co., Inc.	Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef
DK1436397T3 (da)	2001-10-11	2010-08-09	Merck Sharp & Dohme	Hepatitis C virus vaccine
US7479547B2 (en)	2001-10-31	2009-01-20	The South African Medical Research Council	HIV-1 subtype isolate regulatory/accessory genes, and modifications and derivatives thereof
US20060165664A1 (en) *	2002-03-13	2006-07-27	Emini Emilio A	Method of inducing an enhanced immune response against hiv
ATE386824T1 (de)	2002-03-29	2008-03-15	Merck & Co Inc	Verfahren zur virusproduktion
PT1506287E (pt)	2002-05-14	2007-07-17	Merck & Co Inc	Métodos de purificação de adenovírus
CN1490056A (zh) *	2002-10-18	2004-04-21	��¡��ɵ°��̲��о��	针对hiv-1的免疫方法和组合物
EP1553983A2 (fr)	2002-10-23	2005-07-20	Crucell Holland B.V.	Nouveaux parametres pour vaccins a base d'adenoviraux recombinants
US20080153083A1 (en)	2003-10-23	2008-06-26	Crucell Holland B.V.	Settings for recombinant adenoviral-based vaccines
NZ539813A (en)	2002-12-17	2008-04-30	Crucell Holland Bv	A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
US7282365B2 (en)	2003-01-03	2007-10-16	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Rhesus HER2/neu, nucleotides encoding same, and uses thereof
US20070111957A1 (en)	2003-07-21	2007-05-17	Paolo Monaci	Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
GB2406336A (en) *	2003-09-24	2005-03-30	Oxxon Pharmaccines Ltd	HIV Pharmaccines
US8188244B2 (en)	2004-02-11	2012-05-29	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Carcinoembryonic antigen fusions and uses thereof
WO2005080556A2 (fr)	2004-02-23	2005-09-01	Crucell Holland B.V.	Procedes de purification de virus
EP1737885A2 (fr) *	2004-04-12	2007-01-03	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Méthode pour utiliser les vecteurs adénovirals amener une réponse immunitaire
GB0417494D0 (en)	2004-08-05	2004-09-08	Glaxosmithkline Biolog Sa	Vaccine
EP1799836B1 (fr)	2004-10-13	2010-12-22	Crucell Holland B.V.	Vecteurs adenoviraux ameliores et leurs utilisations
US8574595B2 (en)	2005-04-11	2013-11-05	Crucell Holland B.V.	Virus purification using ultrafiltration
TW200716750A (en) *	2005-05-12	2007-05-01	Glaxo Group Ltd	Vaccine composition
AU2012201827B2 (en) *	2005-05-12	2014-09-04	Glaxo Group Limited	Vaccine composition
AU2006301582B2 (en)	2005-10-07	2011-10-13	Msd Italia S.R.L.	Matrix metalloproteinase 11 vaccine
PL2137210T3 (pl) *	2007-03-02	2017-06-30	Glaxosmithkline Biologicals Sa	Nowy sposób i kompozycje
US9717788B2 (en)	2007-03-02	2017-08-01	Glaxosmithkline Biologicals Sa	Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
EP2047861B1 (fr) *	2007-10-12	2019-07-31	Institut Pasteur	Vecteurs de transfert de gène de lentivirus convenant à une administration répétée et leurs applications médicinales
CA2695433A1 (fr)	2007-08-03	2009-02-12	Institut Pasteur	Vecteurs de transfert de genes antiviraux et leurs applications medicinales
WO2009022236A2 (fr)	2007-08-16	2009-02-19	Tripep Ab	Plate-forme immunogène
DK2358757T3 (da) *	2008-11-18	2019-01-02	Beth Israel Deaconess Medical Ct Inc	Antivirale vacciner med forbedret cellulær immunogenicitet
PL2694101T3 (pl)	2011-04-06	2017-07-31	Université Paris Descartes	Kompozycje farmaceutyczne do profilaktyki i lub leczenia choroby HIV u ludzi
PL2825640T3 (pl)	2012-03-12	2016-10-31		Partie rekombinowanych adenowirusów o zmienionych końcach
US8932607B2 (en)	2012-03-12	2015-01-13	Crucell Holland B.V.	Batches of recombinant adenovirus with altered terminal ends
US10106781B2 (en)	2012-11-16	2018-10-23	Beth Israel Deaconess Medical Center, Inc.	Recombinant adenoviruses and use thereof
ES2836432T3 (es)	2015-03-18	2021-06-25	Janssen Vaccines & Prevention Bv	Ensayos para sistemas de expresión recombinante
EP3283634B1 (fr)	2015-04-14	2019-05-22	Janssen Vaccines & Prevention B.V.	Adénovirus recombinant exprimant deux transgènes comprenant un promoteur bidirectionnel
CA3027807A1 (fr)	2016-06-20	2017-12-28	Janssen Vaccines & Prevention B.V.	Promoteur bidirectionnel puissant et equilibre
MX2020004488A (es)	2017-10-31	2020-08-13	Janssen Vaccines & Prevention Bv	Adenovirus y usos de estos.
JP7285833B2 (ja)	2017-10-31	2023-06-02	ヤンセンファッシンズアンドプリベンションベーフェー	アデノウイルス及びその用途
US11872281B2 (en)	2017-10-31	2024-01-16	Janssen Vaccines & Prevention B.V.	Adenovirus and uses thereof
WO2019086461A1 (fr)	2017-10-31	2019-05-09	Janssen Vaccines & Prevention B.V.	Vecteurs d'adénovirus et leurs utilisations
WO2019118480A1 (fr)	2017-12-11	2019-06-20	Beth Israel Deaconess Medical Center, Inc.	Adénovirus recombinés et leurs utilisations
CN111057716B (zh) *	2019-07-27	2022-04-15	中国人民解放军军事科学院军事医学研究院	用于包装重组人4型腺病毒的单质粒载体系统及其应用
CA3156471A1 (fr)	2019-10-03	2021-04-08	Janssen Vaccines & Prevention B.V.	Vecteurs d'adenovirus et leurs utilisations
CN112522276B (zh) *	2020-12-15	2022-07-15	武汉纽福斯生物科技有限公司	一种emc1核苷酸序列及其应用

Citations (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996009399A2 (fr) *	1994-09-23	1996-03-28	Somatix Therapy Corporation	Adenovirus chimerique permettant l'apport de genes
WO1996014061A1 (fr) *	1994-11-03	1996-05-17	Cell Genesys, Inc.	Nouveaux vecteurs adenoviraux, lignees cellulaires d'encapsidation, adenovirus recombines et procedes
WO1999002647A2 (fr) *	1997-07-10	1999-01-21	Hepavec Ag Für Gentherapie	Vecteurs de clonage pour preparer des adenovirus de type virus minimaux
WO1999041397A1 (fr) *	1998-02-17	1999-08-19	Oxford Biomedica (Uk) Limited	Vecteurs antiviraux
WO1999055132A2 (fr) *	1998-04-24	1999-11-04	Introgene B.V.	Production de systemes d'encapsulation de vecteurs d'adenovirus recombinants humains
US6040174A (en) *	1993-05-28	2000-03-21	Transgene S.A.	Defective adenoviruses and corresponding complementation lines
WO2000015819A1 (fr) *	1998-09-11	2000-03-23	The Children's Medical Center Corporation	Lignees de cellules d'encapsidation pour particules de vecteur retroviral derive du vih
WO2000039302A2 (fr) *	1998-12-31	2000-07-06	Chiron Corporation	Expression amelioree de polypeptides hiv et production de particules de type viral
WO2000055341A1 (fr) *	1999-03-17	2000-09-21	Oxford Biomedica (Uk) Limited	Vecteurs antiviraux
WO2000075370A1 (fr) *	1999-06-03	2000-12-14	Oxford Biomedica (Uk) Limited	Procede de selection in vivo permettant de determiner les molecules inhibitrices d'arn
WO2001045748A1 (fr) *	1999-12-22	2001-06-28	Merck & Co., Inc.	Vaccins polynucleotidiques exprimant le gene pol du vih-1 a optimisation des codons et le gene pol du vih-1 modifie
EP1156112A1 (fr) *	2000-05-18	2001-11-21	Geneart GmbH	Gènes synthétiques pour gagpol et leur utilisation
WO2002032943A2 (fr) *	2000-08-14	2002-04-25	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Modifications de env, gag, et pol de vih a pouvoir immunogene augmente aux fins d'immunisation genetique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5643579A (en) *	1984-11-01	1997-07-01	American Home Products Corporation	Oral vaccines
WO1996039178A1 (fr) *	1995-06-05	1996-12-12	The Wistar Institute Of Anatomy And Biology	Recombinant humain du type 5 de l'adenovirus a deficience de replication, utilise comme porteur de vaccins
AU6261696A (en) *	1995-06-05	1996-12-24	Trustees Of The University Of Pennsylvania, The	A replication-defective adenovirus human type 5 recombinant as a vaccine carrier

2001
- 2001-09-14 AU AU2001294562A patent/AU2001294562B2/en not_active Ceased
- 2001-09-14 JP JP2002526335A patent/JP2004508064A/ja not_active Withdrawn
- 2001-09-14 EP EP01975214A patent/EP1320621A4/fr not_active Withdrawn
- 2001-09-14 AU AU9456201A patent/AU9456201A/xx active Pending
- 2001-09-14 CA CA002422882A patent/CA2422882A1/fr not_active Abandoned
- 2001-09-14 WO PCT/US2001/028861 patent/WO2002022080A2/fr active IP Right Grant

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6040174A (en) *	1993-05-28	2000-03-21	Transgene S.A.	Defective adenoviruses and corresponding complementation lines
WO1996009399A2 (fr) *	1994-09-23	1996-03-28	Somatix Therapy Corporation	Adenovirus chimerique permettant l'apport de genes
WO1996014061A1 (fr) *	1994-11-03	1996-05-17	Cell Genesys, Inc.	Nouveaux vecteurs adenoviraux, lignees cellulaires d'encapsidation, adenovirus recombines et procedes
WO1999002647A2 (fr) *	1997-07-10	1999-01-21	Hepavec Ag Für Gentherapie	Vecteurs de clonage pour preparer des adenovirus de type virus minimaux
WO1999041397A1 (fr) *	1998-02-17	1999-08-19	Oxford Biomedica (Uk) Limited	Vecteurs antiviraux
WO1999055132A2 (fr) *	1998-04-24	1999-11-04	Introgene B.V.	Production de systemes d'encapsulation de vecteurs d'adenovirus recombinants humains
WO2000015819A1 (fr) *	1998-09-11	2000-03-23	The Children's Medical Center Corporation	Lignees de cellules d'encapsidation pour particules de vecteur retroviral derive du vih
WO2000039302A2 (fr) *	1998-12-31	2000-07-06	Chiron Corporation	Expression amelioree de polypeptides hiv et production de particules de type viral
WO2000055341A1 (fr) *	1999-03-17	2000-09-21	Oxford Biomedica (Uk) Limited	Vecteurs antiviraux
WO2000075370A1 (fr) *	1999-06-03	2000-12-14	Oxford Biomedica (Uk) Limited	Procede de selection in vivo permettant de determiner les molecules inhibitrices d'arn
WO2001045748A1 (fr) *	1999-12-22	2001-06-28	Merck & Co., Inc.	Vaccins polynucleotidiques exprimant le gene pol du vih-1 a optimisation des codons et le gene pol du vih-1 modifie
EP1156112A1 (fr) *	2000-05-18	2001-11-21	Geneart GmbH	Gènes synthétiques pour gagpol et leur utilisation
WO2002032943A2 (fr) *	2000-08-14	2002-04-25	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Modifications de env, gag, et pol de vih a pouvoir immunogene augmente aux fins d'immunisation genetique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANDRE S ET AL: "INCREASED IMMUNE RESPONSE ELICITED BY DNA VACCINATION WITH A SYNTHETIC GP120 SEQUENCE WITH OPTIMIZED CODON USAGE", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 2, February 1998 (1998-02-01), pages 1497 - 1503, XP002073767, ISSN: 0022-538X *
BRUCE ET AL: "Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus ENV antigen can induce both humoral and CTL immune responses in mice", JOURNAL OF GENERAL VIROLOGY, vol. 80, 1999, pages 2621 - 2628, XP002963542 *
HU Y-W ET AL: "ENZYME ACTIVITIES IN FOUR DIFFERENT FORMS OF HUMAN IMMUNODEFICIENCY VIRUS 1 POL GENE PRODUCTS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 88, no. 11, 1991, pages 4596 - 4600, XP002306309, ISSN: 0027-8424 *
JOSHI S ET AL: "Molecular biology of human immunodeficiency virus Type-1", TRANSFUSION SCIENCE, PERGAMON PRESS, OXFORD, GB, vol. 17, no. 3, September 1996 (1996-09-01), pages 351 - 378, XP004568809, ISSN: 0955-3886 *
KARACOSTAS VELISSARIOS ET AL: "Overexpression of the HIV-1 Gag-Pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles", VIROLOGY, vol. 193, no. 2, 1993, pages 661 - 671, XP002306310, ISSN: 0042-6822 *
MIYAKE KOICHI ET AL: "A new strategy for large scale preparation of high-titer HIV vectors using adenovirus-based expression vectors", BLOOD, vol. 96, 16 November 2000 (2000-11-16), pages 430A *

Also Published As

Publication number	Publication date
JP2004508064A (ja)	2004-03-18
CA2422882A1 (fr)	2002-03-21
EP1320621A2 (fr)	2003-06-25
WO2002022080A2 (fr)	2002-03-21
AU9456201A (en)	2002-03-26
WO2002022080A3 (fr)	2002-05-02
WO2002022080A8 (fr)	2003-01-16
AU2001294562B2 (en)	2007-05-24
WO2002022080A9 (fr)	2003-03-06
AU2001294562B8 (en)	2002-03-26

Publication	Publication Date	Title
AU9456201A (en)	2002-03-26	Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
GB0023008D0 (en)	2000-11-01	Improvements in vaccination
HK1046845A1 (en)	2003-01-30	Vibrator for lower limbs, and chair type vibrator using the vibrator.
HK1035579A1 (en)	2001-11-30	Powder accepting container, powder exhausting device and image generation device.
MXPA02005950A (es)	2003-10-14	Silla.
HK1030166A1 (en)	2001-04-27	Adjuvants for use in vaccines
MXPA02012652A (es)	2003-10-24	Dispositivo para probar saliva y reportar.
EP1324204A4 (fr)	2006-07-26	Procede de fourniture de contenu, equipement de fourniture et equipement d'utilisateur
MX265024B (es)	2009-03-11	Formulaciones de glifosato de potasio.
MXPA03000753A (es)	2003-10-15	Derivados de benzimidazola, su preparacion y su aplicacion terapeutica.
AP2002002659A0 (en)	2002-12-31	3-Nitrogen-6,7-dioxygen steroids and uses related thereto
HUP0202385A2 (en)	2002-10-28	Feline calicivirus genes and vaccines, in particular recombined vaccines
HK1031725A1 (en)	2001-06-22	3-amino-3-arylpropan-1-ol-derivates, their preparation and their use
AU2868601A (en)	2001-08-07	Biaryl compounds, their preparation and their use in therapy
EP1345623A4 (fr)	2005-05-11	Proteoliposomes immunogenes et applications de ceux-ci
EP1242441A4 (fr)	2004-04-14	Vaccins polynucleotidiques exprimant la proteine nef de vih-1 optimisee par codons et proteine nef de vih-1 modifiee
ZA99535B (en)	2000-01-26	Oxygen generating device.
EP1242124A4 (fr)	2004-07-14	Vaccins polynucleotidiques exprimant le gene pol du vih-1 a optimisation des codons et le gene pol du vih-1 modifie
SI1043306T1 (en)	2004-10-31	3-amino-3-arylpropan-1-ol-derivates, their preparation and use
GB9922627D0 (en)	1999-11-24	User interface generation
AU6159001A (en)	2001-11-26	Vaccines, immunotherapeutics and methods for using the same
TW447310U (en)	2001-07-21	Twisting and drawing back type safe syringe
ZA200103440B (en)	2001-10-29	Umpire and soldier interface.
AU2001282290A1 (en)	2002-03-04	Htert-immortalised cell lines, their preparation and use
GB0022724D0 (en)	2000-11-01	Secure messaging

Legal Events

Date	Code	Title	Description
2003-05-09	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2003-06-25	17P	Request for examination filed	Effective date: 20030415
2003-06-25	AK	Designated contracting states	Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
2003-06-25	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO SI
2003-08-27	RIN1	Information on inventor provided before grant (corrected)	Inventor name: CASIMIRO, DANILO, R. Inventor name: TONER, TIMOTHY, J. Inventor name: SHIVER, JOHN, W. Inventor name: KASLOW, DAVID, C. Inventor name: CHEN, LING Inventor name: BETT, ANDREW, J. Inventor name: YOUIL, RIMA Inventor name: EMINI, EMILIO, A.
2005-11-23	A4	Supplementary search report drawn up and despatched	Effective date: 20051007
2006-11-15	17Q	First examination report despatched	Effective date: 20061017
2008-12-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2009-01-21	18D	Application deemed to be withdrawn	Effective date: 20080805